DBV Technologies SA (DBVT)
0.469
-0.02
(-3.91%)
USD |
NASDAQ |
Nov 22, 16:00
0.4662
0.00 (0.00%)
After-Hours: 20:00
DBV Technologies Cash from Investing (Quarterly): -0.109M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -0.109M |
| June 30, 2024 | 0.691M |
| March 31, 2024 | -2.132M |
| December 31, 2023 | -0.187M |
| September 30, 2023 | -0.322M |
| June 30, 2023 | -0.341M |
| March 31, 2023 | 0.042M |
| December 31, 2022 | -0.034M |
| September 30, 2022 | 0.152M |
| June 30, 2022 | -0.229M |
| Date | Value |
|---|---|
| March 31, 2022 | 0.011M |
| December 31, 2021 | -0.474M |
| September 30, 2021 | 0.054M |
| June 30, 2021 | 0.172M |
| March 31, 2021 | -0.185M |
| December 31, 2020 | -0.633M |
| September 30, 2020 | -0.782M |
| June 30, 2020 | -0.52M |
| March 31, 2020 | -0.93M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-2.132M
Minimum
Mar 2024
0.691M
Maximum
Jun 2024
-0.3029M
Average
-0.187M
Median
Dec 2023
Cash from Investing (Quarterly) Benchmarks
| Edap TMS SA | -1.120M |
| Genfit SA | -- |
| Cellectis SA | 22.33M |
| Adaptimmune Therapeutics PLC | -66.02M |
| Akari Therapeutics PLC | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -22.46M |
| Cash from Financing (Quarterly) | 0.007M |
| Free Cash Flow | -108.72M |
| Free Cash Flow Per Share (Quarterly) | -0.2376 |
| Free Cash Flow Yield | -241.1% |